OncoMatch/Clinical Trials/NCT06511726
Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
Is NCT06511726 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cadonilimab for cervical cancer.
Treatment: Cadonilimab — This is a Phase II clinical study for patients with locally advanced cervical cancer, aimed at evaluating the efficacy, safety, and tolerability of Cadonilimab combined with chemotherapy as induction therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC1, IIIC2, IVA (FIGO 2018)
Initial diagnosis of stage IB3-IVA (according to FIGO 2018 staging)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Previously received immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies) or any treatment targeting tumor immune mechanisms involving immune co-stimulatory factors (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40)
Lab requirements
Blood counts
Main organ functions meet the protocol criteria within 7 days before treatment
Kidney function
Main organ functions meet the protocol criteria within 7 days before treatment
Liver function
Main organ functions meet the protocol criteria within 7 days before treatment
Cardiac function
Any of the following cardiovascular diseases: NYHA ≥ II for heart failure, severe arrhythmias requiring long-term drug intervention, cerebrovascular events (CVA) within 6 months, LVEF < 50%
Main organ functions meet the protocol criteria within 7 days before treatment. Any of the following cardiovascular diseases: a) New York Heart Association (NYHA) functional classification ≥ II for heart failure. b) Presence of severe arrhythmias requiring long-term drug intervention asymptomatic patients with stable ventricular rate in atrial fibrillation are allowed to enroll. c) Occurrence of cerebrovascular events (CVA) within 6 months . d) Left ventricular ejection fraction (LVEF) < 50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify